News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure has published its financial report for the first quarter of 2024. The company is progressing, as anticipated, the next steps in the development of its clinical and pre-clinical programmes
17 May 2024
Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
29 March 2024
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
22 March 2024
Molecure has submitted a new application for approval to conduct a Phase II clinical trial for clinical candidate OATD-01 in the countries of the European Union and Norway
9 February 2024
Molecure invites to the R&D Day – an online scientific and educational meeting on February 6, 2024
29 January 2024